Compare CFG & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFG | BIIB |
|---|---|---|
| Founded | 1828 | 1978 |
| Country | United States | United States |
| Employees | 17398 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7B | 27.3B |
| IPO Year | N/A | 1996 |
| Metric | CFG | BIIB |
|---|---|---|
| Price | $63.10 | $193.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 25 |
| Target Price | $70.17 | ★ $206.83 |
| AVG Volume (30 Days) | ★ 3.3M | 1.0M |
| Earning Date | 04-16-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.15 |
| Revenue | N/A | ★ $9,890,600,000.00 |
| Revenue This Year | $20.17 | N/A |
| Revenue Next Year | $8.30 | N/A |
| P/E Ratio | ★ $16.85 | $88.14 |
| Revenue Growth | N/A | ★ 2.22 |
| 52 Week Low | $39.40 | $121.06 |
| 52 Week High | $68.79 | $205.97 |
| Indicator | CFG | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 53.78 |
| Support Level | $58.09 | $170.52 |
| Resistance Level | $66.24 | $204.19 |
| Average True Range (ATR) | 1.42 | 5.61 |
| MACD | -0.10 | -0.64 |
| Stochastic Oscillator | 52.36 | 35.44 |
Citizens Financial Group Inc is a bank holding company headquartered in Providence, Rhode Island. Through its subsidiaries, it offers various retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations, and institutions. The group's reportable business segments are: Consumer Banking and Commercial Banking. The majority of its revenue is generated from the Consumer Banking segment, which serves consumer customers and small businesses, offering traditional banking products and services, including deposits, mortgage and home equity lending, credit cards, small business loans, education loans, point-of-sale finance loans, and wealth management solutions, among others, through a network of branches and ATMs.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).